Analyzing Intuitive Surgical (NASDAQ:ISRG) & Pathfinder Cell Therapy (OTCMKTS:PFND)
based on the strength of their analyst recommendations, valuation, earnings, dividends, profitability, institutional ownership and risk. Pathfinder is better based on analyst recommendations and earnings. Intuitive is better based on valuation and dividends.
Which is the best stock? We will compare the two companies based on their analyst ratings, valuation, risks, profitability, institutional owners, earnings, and dividends.
Risk & Volatility
Pathfinder Cell Therapy's stock price has a beta value of -0.09 which means that it is 109% less volatile compared to the S&P 500. This table compares the net margins of Pathfinder Cell Therapy with Intuitive Surgical, as well as their return on equity and assets.
Net Margins
Return on Equity
Return on Assets
Pathfinder Cell Therapy
N/A
N/A
N/A
The Intuitive Surgical
20.40%
11.32%
9.85%
Earnings and Value
This table compares Pathfinder Cell Therapy's top line revenue, earnings per shares and valuation with Intuitive Surgical.
Gross Revenue
Price/Sales Ratio
Net Income
Earnings per Share
Price/Earnings ratio
Pathfinder Cell Therapy
N/A
N/A
N/A
N/A
N/A
The Intuitive Surgical
$6.22 billion
16.90
$1.32 billion
$3.66
82.03
Intuitive Surgical's revenue and earnings are higher than Pathfinder Cell Therapy.
Analyst Recommendations
MarketBeat has published a list of recent recommendations made by Pathfinder Cell Therapy, Intuitive Surgery and other companies.
Sell Ratings
Hold Ratings
Buy Ratings
Strong Buy Ratings
Rating Score
Pathfinder Cell Therapy
0
0
0
0
N/A
The Intuitive Surgical
0
5
15
0
2.75
Intuitive surgical has a consensus target price of $299.40. This indicates a possible downside of 0.27%.
Insiders and Institutional Ownership
Institutional investors own 82.0% Intuitive Surgical's shares. Insiders own 15.1% of Pathfinder Cell Therapy's shares. In contrast, only 0.9% of Intuitive Surgical's shares are held by insiders. A stock with a high level of institutional ownership indicates that hedge funds, money managers and endowments are confident the stock will perform better than the market in the long run.
You can read more about it here:
Pathfinder Cell Therapy is beaten by Intuitive Surgery on 7 out of 8 factors.
What is Pathfinder Cell Therapy?
Get Rating
)
Pathfinder Cell Therapy, Inc., a regenerative medicine development company, is in the early stages of its growth. It is focused on developing a new cell-based treatment for diabetes, kidney disease, myocardial ischemia, and other diseases that are characterized by specific organ cell damage. The company was established in August 1990 with its headquarters in Cambridge, MA.
What is Intuitive Surgery?
Get Rating
)
Intuitive Surgical, Inc. provides robotic-assisted surgery solutions and invasive treatment through a comprehensive ecosystem. Da Vinci Surgical, Ion Endoluminal Systems and other products are among its offerings. MarketBeat.com offers a FREE daily email newsletter
.